Section Arrow
Quote
PCSA.NASDAQ
- Processa Pharmaceuticals
Quotes are at least 15-min delayed:2024/05/05 13:55 EDT
Last
 2.17
-0.09 (-3.98%)
Day High 
2.3 
Prev. Close
2.26 
1-M High
3.305 
Volume 
91.44K 
Bid
2.09
Ask
2.21
Day Low
2.15 
Open
2.3 
1-M Low
1.4 
Market Cap 
6.45M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 1.97 
20-SMA 2 
50-SMA 2.18 
52-W High 18 
52-W Low 1.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.48/-1.89
Enterprise Value
6.52M
Balance Sheet
Book Value Per Share
1.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.318+0.0248+8.46%-- 
VAXXVaxxinity0.1411+0.0369+35.41%-- 
DNAGinkgo Bioworks Holdings0.955+0.0939+10.90%-- 
ARDXArdelyx8.72+1.93+28.42%-- 
IBRXImmunityBio9.15+0.18+2.01%-- 
Quotes are at least 15-min delayed：2024/05/05 13:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.